Compare OCC & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | PYPD |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 85.1M |
| IPO Year | 2001 | 2014 |
| Metric | OCC | PYPD |
|---|---|---|
| Price | $12.61 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 261.1K | 79.1K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,828,590.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $2.44 | $2.44 |
| 52 Week High | $13.95 | $5.12 |
| Indicator | OCC | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 66.41 |
| Support Level | $6.81 | $4.15 |
| Resistance Level | $13.65 | $5.05 |
| Average True Range (ATR) | 1.24 | 0.25 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 83.85 | 92.39 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.